Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 16.2% in February

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 22,700 shares, a decrease of 16.2% from the January 31st total of 27,100 shares. Based on an average trading volume of 600,700 shares, the days-to-cover ratio is presently 0.0 days. Approximately 6.0% of the shares of the company are short sold.

Exicure Price Performance

Shares of Exicure stock opened at $14.28 on Wednesday. The firm has a fifty day moving average price of $10.96 and a 200 day moving average price of $8.62. Exicure has a 1 year low of $1.44 and a 1 year high of $36.00. The stock has a market cap of $37.21 million, a PE ratio of -6.90 and a beta of 3.76.

Institutional Investors Weigh In On Exicure

A hedge fund recently bought a new stake in Exicure stock. Geode Capital Management LLC acquired a new position in shares of Exicure, Inc. (NASDAQ:XCUR) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned 0.48% of Exicure at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.82% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.